Gyre Therapeutics (GYRE) Cash from Financing Activities (2010 - 2026)
Gyre Therapeutics (GYRE) reported Cash from Financing Activities of $21000.0 for Q1 2026, down 98.44% year-over-year from $1.3 million in Q1 2025, and down 93.4% on a QoQ basis from $318000.0 in Q4 2025.
Gyre Therapeutics (GYRE) has 17 years of Cash from Financing Activities data on file, last reported at $21000.0 in Q1 2026.
- Quarterly Cash from Financing Activities fell 98.44% year-over-year to $21000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23.1 million (up 726.94% YoY) and the FY2025 annual result came in at $24.4 million, up 1059.75% from the prior year.
- Cash from Financing Activities eased to $21000.0 in Q1 2026 per GYRE's latest filing, from $318000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $22.4 million in Q2 2025 and bottomed at -$45.0 million in Q3 2022.
- The 5-year median for Cash from Financing Activities is $318000.0 (2025), against an average of -$1.1 million.
- The widest annual swing landed in 2023, when Cash from Financing Activities plunged 48612.5%; it then surged 14227.56% in 2025.
- Tracing GYRE's Cash from Financing Activities over 5 years: stood at -$45.0 million in 2022, then soared by 133.85% to $15.2 million in 2023, then tumbled by 93.67% to $964000.0 in 2024, then tumbled by 67.01% to $318000.0 in 2025, then slumped by 93.4% to $21000.0 in 2026.
- Per Business Quant, the three latest GYRE Cash from Financing Activities figures stand at $21000.0 (Q1 2026), $318000.0 (Q4 2025), and $365000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 7.00 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -600,000.00 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 53,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -538.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -802.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 15.71 Mn |
| 10 | Gyre Therapeutics | 532.38 Mn | 518.25 Mn | 8.38 Mn | 21,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21,000.00 |
| Mar 31, 2026 | 21,000.00 |
| Dec 31, 2025 | 318,000.00 |
| Dec 31, 2025 | 318,000.00 |
| Sep 30, 2025 | 365,000.00 |
| Sep 30, 2025 | 365,000.00 |
| Jun 30, 2025 | 22.35 Mn |
| Jun 30, 2025 | 22.35 Mn |
| Mar 31, 2025 | 1.34 Mn |
| Mar 31, 2025 | 1.34 Mn |
| Dec 31, 2024 | 964,000.00 |
| Dec 31, 2024 | 964,000.00 |
| Sep 30, 2024 | 324,000.00 |
| Sep 30, 2024 | 324,000.00 |
| Jun 30, 2024 | 156,000.00 |
| Jun 30, 2024 | 156,000.00 |
| Mar 31, 2024 | 658,000.00 |
| Mar 31, 2024 | 658,000.00 |
| Dec 31, 2023 | 15.24 Mn |
| Dec 31, 2023 | 15.24 Mn |
| Sep 30, 2023 | -1.48 Mn |
| Sep 30, 2023 | -1.48 Mn |
| Jun 30, 2023 | -3.50 Mn |
| Jun 30, 2023 | -3.50 Mn |
| Mar 31, 2023 | -7.76 Mn |
| Mar 31, 2023 | -7.76 Mn |
| Sep 30, 2022 | -45.03 Mn |
| Sep 30, 2022 | -45.03 Mn |
| Mar 31, 2022 | 16,000.00 |
| Mar 31, 2022 | 16,000.00 |
| Sep 30, 2021 | 98,000.00 |
| Sep 30, 2021 | 98,000.00 |
| Jun 30, 2021 | -4,000.00 |
| Jun 30, 2021 | -4,000.00 |
| Mar 31, 2021 | 49.46 Mn |
| Mar 31, 2021 | 49.46 Mn |
| Sep 30, 2020 | -75,000.00 |
| Sep 30, 2020 | -75,000.00 |
| Jun 30, 2020 | 28.09 Mn |
| Jun 30, 2020 | 28.09 Mn |
| Mar 31, 2020 | 32.36 Mn |
| Mar 31, 2020 | 32.36 Mn |
| Sep 30, 2019 | 92,000.00 |
| Sep 30, 2019 | 92,000.00 |
| Jun 30, 2019 | 129,000.00 |
| Jun 30, 2019 | 129,000.00 |
| Mar 31, 2019 | 106,000.00 |
| Mar 31, 2019 | 106,000.00 |
| Dec 31, 2018 | 71,000.00 |
| Dec 31, 2018 | 71,000.00 |
| Jun 30, 2018 | 37,000.00 |
| Jun 30, 2018 | 37,000.00 |
| Mar 31, 2018 | 111.22 Mn |
| Mar 31, 2018 | 111.22 Mn |
| Dec 31, 2017 | 10.94 Mn |
| Dec 31, 2017 | 10.94 Mn |
| Sep 30, 2017 | -282,000.00 |
| Sep 30, 2017 | -282,000.00 |
| Jun 30, 2017 | 15.40 Mn |
| Jun 30, 2017 | 15.40 Mn |
| Mar 31, 2017 | -4.97 Mn |
| Mar 31, 2017 | -4.97 Mn |
| Dec 31, 2016 | 83,000.00 |
| Dec 31, 2016 | 83,000.00 |
| Sep 30, 2016 | 710,000.00 |
| Sep 30, 2016 | 710,000.00 |
| Dec 31, 2015 | 167,000.00 |
| Dec 31, 2015 | 167,000.00 |
| Sep 30, 2015 | 3.98 Mn |
| Sep 30, 2015 | 3.98 Mn |
| Jun 30, 2015 | 1.88 Mn |
| Jun 30, 2015 | 1.88 Mn |
| Mar 31, 2015 | 3.28 Mn |
| Mar 31, 2015 | 3.28 Mn |
| Sep 30, 2014 | 1.74 Mn |
| Sep 30, 2014 | 1.74 Mn |
| Jun 30, 2014 | -195,000.00 |
| Jun 30, 2014 | -195,000.00 |
| Mar 31, 2014 | 3.47 Mn |
| Mar 31, 2014 | 3.47 Mn |
| Dec 31, 2013 | 6.27 Mn |
| Dec 31, 2013 | 6.27 Mn |
| Sep 30, 2013 | -160,000.00 |
| Sep 30, 2013 | -160,000.00 |
| Jun 30, 2013 | -164,000.00 |
| Jun 30, 2013 | -164,000.00 |
| Mar 31, 2013 | -206,000.00 |
| Mar 31, 2013 | -206,000.00 |
| Dec 31, 2012 | -195,000.00 |
| Dec 31, 2012 | -195,000.00 |
| Sep 30, 2012 | 224,000.00 |
| Sep 30, 2012 | 224,000.00 |
| Jun 30, 2012 | -148,000.00 |
| Jun 30, 2012 | -148,000.00 |
| Mar 31, 2012 | -507,000.00 |
| Mar 31, 2012 | -507,000.00 |
| Dec 31, 2011 | -538,000.00 |
| Dec 31, 2011 | -538,000.00 |
| Sep 30, 2011 | -521,000.00 |
| Sep 30, 2011 | -521,000.00 |
| Jun 30, 2011 | 83.31 Mn |
| Jun 30, 2011 | 83.31 Mn |
| Mar 31, 2011 | 567,000.00 |
| Mar 31, 2011 | 567,000.00 |
| Dec 31, 2010 | 2.01 Mn |
| Dec 31, 2010 | 2.01 Mn |
| Sep 30, 2010 | 1.20 Mn |
| Sep 30, 2010 | 1.20 Mn |